BioLineRx (NASDAQ: BLRX) reported Q1 EPS of $0.00, $0.16 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $6.85 million versus the consensus estimate of $1.82 million.

For earnings history and earnings-related data on BioLineRx (BLRX) click here.